Benefits of Low Dose Nivolumab Plus Triple Metronomic Chemotherapy in Advanced Head & Neck Cancer
Not Applicable
- Conditions
- Health Condition 1: C049- Malignant neoplasm of floor of mouth, unspecifiedHealth Condition 2: C009- Malignant neoplasm of lip, unspecifiedHealth Condition 3: C069- Malignant neoplasm of mouth, unspecifiedHealth Condition 4: C109- Malignant neoplasm of oropharynx,unspecifiedHealth Condition 5: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynxHealth Condition 6: C029- Malignant neoplasm of tongue, unspecified
- Registration Number
- CTRI/2023/10/059116
- Lead Sponsor
- Dr Santosh Kumar Swain
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Adults with advanced HNSCC
2. With an Eastern Cooperative Oncology Group performance status of 0-2
3. Who were planned for palliative systemic therapy
4. With normal organ function
5. At least one measurable lesion.
6. Biopsy proven
7. Inoperable and metastatic
8. Platinum sensitive and refractory as well.
Exclusion Criteria
1. Patients less than 18 years of age
2. Patients not meeting the above-mentioned criteria
3. Patients or patient relatives who do not consent
4. Pregnant and lactating females.
5. Patients on any other investigational agent(s)
6. Patients with autoimmune disease
7. Patients receiving immunosuppressants
8. Patients with uncontrolled comorbidities
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method